New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
05:55 EDTABT, ABT, BSX, BSX, JNJ, JNJ, MDT, MDT, STJ, STJ, EW, EW, ATRC, ATRC, HT, HTLeerink's medical supplies and devices analyst holds a luncheon
Medical Supplies & Devices Analyst Antalffy holds a luncheon meeting where the focus is on current market paradigms and future growth drivers in interventional cardiology at the Variety Club Research Center at the University of Minnesota, Minneapolis on March 20 at 11 am.
News For ABT;BSX;JNJ;MDT;STJ;EW;ATRC;HT From The Last 14 Days
Check below for free stories on ABT;BSX;JNJ;MDT;STJ;EW;ATRC;HT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 14, 2014
06:44 EDTBSXBoston Scientific upgraded at BofA/Merrill
As previously reported, BofA/Merrill upgraded Boston Scientific to Buy from Neutral. The firm upgraded shares given increased confidence in the pipeline, opportunities to increase margin, valuation, and expectations the FDA will approve the LAA product this year. Price target raised to $16.
06:22 EDTMDT, EWMedtronic downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
06:21 EDTEW, MDTEdwards Lifesciences upgraded to Neutral from Underweight at JPMorgan
Subscribe for More Information
06:18 EDTBSXBoston Scientific upgraded to Buy from Neutral at BofA/Merrill
Price target is $16.
05:56 EDTJNJJohnson & Johnson downgraded to Hold from Buy at Jefferies
Jefferies downgraded its rating on Johnson & Johnson (JNJ) to Hold citing the recent outperformance of shares. The firm keeps a $105 price target for the stock.
April 13, 2014
15:10 EDTMDT, EWMedtronic says CoreValve ruling has no impact outside U.S.
Subscribe for More Information
April 12, 2014
19:50 EDTEW, MDTEdwards says court limits sale of Medtronic CoreValve system in U.S.
Edwards Lifesciences (EW) announced that the U.S. District Court for the District of Delaware granted a preliminary injunction limiting the sale of Medtronic's (MDT) CoreValve system in the United States. The court ordered the injunction to go into effect in seven business days. The hearing related to a federal jury decision in 2010 that CoreValve willfully infringes Edwards' U.S. Andersen transcatheter aortic valve replacement patent. At the conclusion of the hearing, Chief Judge Gregory Sleet ordered Edwards and Medtronic to confer on what instances the CoreValve device could continue to be used in the treatment of U.S. patients at centers currently trained on CoreValve. There is a large body of evidence demonstrating the safety and performance of the Edwards SAPIEN valves, and the company remains committed to ensuring patients have appropriate access to transcatheter therapy. This case was initiated by Edwards in 2008. On April 1, 2010, a federal jury found Medtronic willfully infringed Edwards' U.S. Andersen patent and awarded damages. In Nov. 2012, the U.S. Court of Appeals for the Federal Circuit affirmed the jury decision; in Oct. 2013, the U.S. Supreme Court declined to hear Medtronic's appeal. The patent involved in this suit is part of the Andersen family of patents. The U.S. Andersen patent was issued in 1995. A petition has been filed with the U.S. Patent and Trademark Office to extend this patent into early 2016. In a separate case, a federal jury in January found that Medtronic CoreValve had willfully infringed Edwards' U.S. Cribier transcatheter heart valve patent, and awarded damages to Edwards in that trial.
April 11, 2014
18:44 EDTJNJJ&J halting development of Botox competitor, WSJ says
Subscribe for More Information
April 10, 2014
19:10 EDTMDTMedtronic confirms FDA approval for expanded indications
Subscribe for More Information
18:34 EDTBSXBoston Scientific enrolls first patient in registry for evaluating Vercise DBS
Subscribe for More Information
16:32 EDTMDTMedtronic gets FDA approval for revised labeling application
The U.S. FDA approved an application from Medtronic for revised labeling for two cardiac resynchronization pacemakers and eight cardiac resynchronization defibrillators, expanding the indication for use to patients with atrioventricular block and less severe heart failure. The FDA previously approved these devices for patients with more severe heart failure as evaluated by their physician using specific criteria. The new approved use includes patients with less severe heart failure, but who are already indicated to receive RV pacing. With the new indication, these patients will be eligible to receive a device that will pace both sides of their heart instead of just the right. Reference Link
08:34 EDTABTAbbott completes enrollment of Absorb clinical trials in U.S., Japan and China
Subscribe for More Information
April 9, 2014
11:43 EDTABTGilead defended by analysts after recent pullback
Subscribe for More Information
08:24 EDTATRCPiper Jaffray's medtech analysts hold an analyst/industry conference call
The MedTech Analyst Team focuses on Piper Jaffray's covered universe from the perspective of Technical Analyst Johnson ahead of 1Q14 earnings results on an Analyst/Industry conference call to be held on April 11 at 10 am.
07:23 EDTJNJEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
07:09 EDTJNJJohnson & Johnson outlook positive into Q1 results, says Bernstein
Bernstein expects Johnson & Johnson's Q1 EPS to come in slightly above the consensus estimate, with strength in pharmaceuticals more than offsetting lackluster Medical Devices & Diagnostics growth, according to the firm. Bernstein keeps an Outperform rating on the stock.
April 8, 2014
07:26 EDTJNJ, MDT, EWElsevier Business Intelligence to hold a conference
Subscribe for More Information
April 7, 2014
18:01 EDTBSXBoston Scientific gets FDA, CE Mark clearance for Expect Slimline Needle
Boston Scientific announced it has received clearance from the U.S. FDA and CE Mark approval in Europe for the Expect Slimline Needle, which is now globally available for Endoscopic Ultrasound-Fine Needle Aspiration procedures. The Expect Slimline Needle is on contract with four leading group purchasing organizations.
07:58 EDTMDTMedtronic data positive for C.R. Bard, says Barclays
Barclays said Medtronic's (MDT) better than expected drug coated balloon data could have a positive class effect that benefits C.R. Bard (BCR). The firm reiterates its Overweight rating C.R. Bard and raised its price target to $165 from $160. Note that BofA/Merrill downgraded C.R. Bard to Neutral from Buy following the Medtronic's news.
07:38 EDTMDTMedtronic data should lead to approval of drug-coated balloon, says Wells Fargo
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use